Exciting Medical Lead Oncology position in an innovative biopharmaceutical company
Nykode Therapeutics is seeking a strategy-driven Medical Lead Oncology to join the Oncology team.
As Medical Lead Oncology at Nykode Therapeutics, you will create and drive the clinical development strategy in a product-specific Oncology area.
Your main tasks are:
Your qualifications include a minimum of eight years of experience in oncology and immunotherapy, covering clinical development from pharma/ biotech. Additionally, you have demonstrated adept leadership in steering cross-functional clinical research projects. You are well-versed in managing Contract Research Organisations and proficient in overseeing and nurturing relationships with external partners.
You are a MD w/ wo PhD, preferably with Oncology experience and/or Specialty.
You embrace a forward-thinking mindset prioritising innovative ideas while upholding quality standards, structure, and accuracy. Your work reflects exceptional individual initiative, organisational skills, and the ability to drive projects with determination.
As an effective communicator and attentive listener, you are masterful in conveying information with clarity and empathy, a cornerstone for establishing trust.
Nykode Therapeutics offers an opportunity to be a highly visible member of the medical team, where you will have room to influence your role and enhance your skills in clinical development strategy of oncology vaccines.
Nykode is looking for individuals who are inspired by the Nykode technology and the quest to unlock the future of medicine. Nykode is eager to hire people who seek out environments that offer creative challenges and provide growth opportunities.
Travelling: Limited.
Domicile: Oslo Norway, or Kongens Lyngby, Denmark.
For more details about the job or the company, please contact Director Gert Vium Andersen, Unique Human Capital, on mobile: +45 42 95 08 83.
All applications must be in English and are treated confidentially.
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on treatment of cancer and autoimmune diseases. Nykode’s modular vaccine technology specifically targets antigens to APC, which have been shown to induce broad, strong and long-lasting antigen specific immune responses which correlates with clinical responses in cancer.
Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of cervical cancer; and VB10.NEO, an individualized cancer neoantigen vaccine, which is exclusively out-licensed to Genentech, a member of the Roche Group.
The Company’s partnerships include Genentech within oncology and a multi-target collaboration with Regeneron within oncology and infectious diseases.
Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Read more at https://nykode.com/
Vi er over 200 mennesker, der arbejder med viden, kreativitet og teknologi
